Insulin secretion from pancreatic b-cells plays the central role in glucose homeostasis; its impairment is a major factor in the development of diabetes and is a target for treatment of the disease. cAMP is a key second messenger in b-cells that amplifies insulin secretion. In addition, incretin hormones such as glucagon-like peptide 1 (GLP-1) released by the gut stimulate insulin secretion through cAMP signaling in b-cells, which is the basis for the incretin-based diabetes therapies being used worldwide. Despite its importance, the mechanism of cAMP-induced insulin secretion is still unknown. Utilizing differential metabolomics-based approach, we find that cAMP-induced insulin secretion consists primarily of two critical mechanisms: activation by glucose of the malate-aspartate (MA) shuttle, a NADH shuttle linked to glycolysis, to produce glutamate, which confers cAMP responsiveness, and uptake of glutamate into insulin granules through VGLUT1 by cAMP signaling, which is required for insulin release. Thus, glutamate is a crucial signal linking glucose metabolism and cAMP action in insulin secretion. Since amplification of insulin secretion by incretins are critical to maintain normal blood glucose levels, dissection of the mechanism of cAMPinduced insulin may open new avenues for therapeutic strategies to improve insulin secretion in diabetes. Metabolomics is a useful tool to identify a known metabolite acting as an unexpected signal in cell function. In this lecture, I will discuss cell signaling in insulin secretion, focusing mainly on the role of cAMP signaling, based on our recent studies. Incretin Action in the Cardiovascular System
Daniel J Drucker Medicine, Mt. Sinai Hospital, University of Toronto, Canada Type 2 diabetes is associated with increased risk of heart attacks, strokes, and both microvascular and macrovascular disease. Although control of glucose significantly attenuates the development and progression of microvascular disease, the rates of macrovascular disease are not significantly reduced by improvements in glycemic control in studies of medium term duration. Nonglycemic actions of diabetes medications may impact multiple risk factors that contribute to the development of cardiovascular disease. This lecture examines concepts surrounding the biology of the incretin hormones in the cardiovascular system, and provides a mechanistic overview of how GLP-1 actions in the immune system, blood vessels, cardiomyocytes, the intestine, kidney and the liver, may modulate the risk of developing cardiovascular disease in subjects with type 2 diabetes. Diabetes is a worldwide public health problem requiring a multilevel response. Diabetes education has been recognized as an essential part of diabetes care. In the past, diabetes education mainly involved the transfer of information from a healthcare professional to a patient. Using the compliance, adherence model to guide care, the healthcare provider served as the expert and the patient was a passive recipient of information. The ultimate goal of diabetes education was improved glycemic control, and clinicians believed that a well-educated patient would provide good self care. Things have changed. It became clear that although knowledge in an essential prerequisite for self-care; Knowledge alone is not enough to promote behavior change. The process of diabetes education evolved from information delivery to a focus on techniques that promote effective self-management. The goals of diabetes education now encompass improved quality of life, self-care behavior leading to improvements in a wide variety of clinical attributes, and decreased healthcare costs. Diabetic complications are the leading causes of kidney failure, blindness, limb amputation and cardiovascular disease in developed countries. Most of the major risk factors are known to be related to hyperglycemia, insulin resistance, dyslipidemia and hypertension. Most studies have focused on these risk factors and their mechanisms in causing vascular complications. However, translating results from cell based or animal studies to effective therapeutic agents have been difficult. Recently, interest has shifted to identifying endogenous protective factors which can prevent or delay the progression of diabetic complications. Clinical longitudinal studies have shown that in a small number of diabetic patients of extreme duration, such as in the Joslin Medalist Study, those potential endogenous factors exist which can prevent the onset or progression of diabetic nephropathy and retinopathy, even in the presence of hyperglycemia. Of the 700 patients studied, 40% do not have significant eye or kidney disease where potential protective factors have been identified in the plasma for the retina and kidneys. Recent work with insulin has shown that it is an important hormone which has anti-atherogenic actions and anti-ischemic effects. Mechanistic studies suggest that hyperglycemia's toxic effects activate inflammation or oxidative stress via the NF-jB pathway, but independently, hyperglycemia is also capable of inducing vascular pathology by inhibiting endogenous protective factors. Future studies regarding diabetic complications will need to identify important endogenous factors, in addition to insulin, which can prevent, delay, or neutralize the toxic effects of hyperglycemia in order to develop clinically effective therapeutics for diabetic retinopathy and nephropathy.
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